AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 1 filers reported holding AVADEL PHARMACEUTICALS PLC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,965,528 | -37.5% | 967,527 | 0.0% | 3.05% | +9.0% |
| Q2 2023 | $15,944,845 | +23.5% | 967,527 | -31.4% | 2.80% | +4.9% |
| Q1 2023 | $12,910,186 | +173.4% | 1,409,409 | +113.7% | 2.67% | +162.6% |
| Q4 2022 | $4,721,368 | +42.9% | 659,409 | 0.0% | 1.02% | +31.9% |
| Q3 2022 | $3,304,000 | +105.3% | 659,409 | 0.0% | 0.77% | +79.5% |
| Q2 2022 | $1,609,000 | -64.3% | 659,409 | 0.0% | 0.43% | -62.2% |
| Q1 2022 | $4,504,000 | -15.5% | 659,409 | 0.0% | 1.13% | +9.7% |
| Q4 2021 | $5,328,000 | -1.0% | 659,409 | +20.1% | 1.03% | +22.4% |
| Q3 2021 | $5,383,000 | +45.6% | 549,250 | 0.0% | 0.84% | +85.3% |
| Q2 2021 | $3,696,000 | -25.6% | 549,250 | 0.0% | 0.46% | -50.2% |
| Q1 2021 | $4,965,000 | +71.1% | 549,250 | +26.5% | 0.92% | +213.7% |
| Q4 2020 | $2,901,000 | – | 434,250 | – | 0.29% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WEALTH EFFECTS LLC | 2,409,289 | $24,815,676 | 12.25% |
| Knoll Capital Management, LLC | 600,000 | $6,180,000 | 6.42% |
| Vivo Capital, LLC | 4,096,428 | $42,193,208 | 4.62% |
| GENDELL JEFFREY L | 5,615,350 | $57,838,105 | 3.29% |
| Tri Locum Partners LP | 983,602 | $10,131,101 | 3.24% |
| Samsara BioCapital, LLC | 967,527 | $9,965,528 | 3.05% |
| MPM BioImpact LLC | 664,224 | $6,841,507 | 1.83% |
| COWEN AND COMPANY, LLC | 2,338,302 | $24,084,510 | 1.68% |
| RTW INVESTMENTS, LP | 7,136,415 | $73,505,075 | 1.55% |
| TANG CAPITAL MANAGEMENT LLC | 1,000,000 | $10,300,000 | 1.45% |